April 25 (Reuters) - EMA:
EMA SAYS CHMP WILL RE-EXAMINE OPINION ADOPTED FOR MARKETING AUTHORISATION HOLDER FOR KISUNLA (DONANEMAB)
EMA SAYS CHMP RECOMMENDS CONDITIONAL MARKETING AUTHORISATION FOR DUVYZAT (GIVINOSTAT), AS TREATMENT FOR DMD IN PATIENTS FROM AGE SIX WHO CAN WALK
EMA SAYS TEPEZZA (TEPROTUMUMAB) RECEIVED POSITIVE OPINION FROM CHMP FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE THYROID EYE DISEASE
EMA SAYS SEPHIENCE (SEPIAPTERIN) GOT POSITIVE OPINION FROM CHMP FOR TREATMENT OF HYPERPHENYLALANINAEMIA IN ADULTS & CHILDREN WITH PHENYLKETONURIA
EMA SAYS CHMP RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR ZIIHERA (ZANIDATAMAB)
Source text: [ID:]
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.